Table 6 Summary of findings, including GRADE quality assessment for the comparison between elagolix and elagolix with estradiol/norethindrone acetate by subgroup analysis
Outcome/Subgroup | No of trials | No of participants | Risk Ratio (RR) | 95% Confidence interval (CI) | P value | Random effect; I2 statistic | GRADE quality | |
|---|---|---|---|---|---|---|---|---|
Reduction of menstrual blood loss of less than 80 ml | ||||||||
Dosage of E2/NETA | 0.5 mg E2/ 0.1 mg NETA | 2 | 333 | 1.08 | 0.92, 1.27 | P = 0.350 | 52% | Moderate |
1.0 mg E2/ 0.5 mg NETA | 4 | 1165 | 1.08 | 1.00, 1.18 | P = 0.060 | 58% | Moderate | |
Uterine volume | < 500 cm3 | 3 | 894 | 1.07 | 0.95, 1.21 | P = 0.250 | 70% | Low |
> 500 cm3 | 2 | 471 | 1.08 | 0.94, 1.24 | P = 0.290 | 46% | Moderate | |
Reduction of more than 50% menstrual blood loss | ||||||||
Dosage of E2/NETA | 0.5 mg E2/ 0.1 mg NETA | 2 | 333 | 1.10 | 1.01, 1.19 | P = 0.020 | 0% | Moderate |
1.0 mg E2/ 0.5 mg NETA | 4 | 1165 | 1.08 | 0.99, 1.17 | P = 0.070 | 56% | Moderate | |
Uterine volume | < 500 cm3 | 3 | 894 | 1.07 | 0.95, 1.21 | P = 0.250 | 70% | Low |
> 500 cm3 | 2 | 471 | 1.10 | 1.02, 1.17 | P = 0.009 | 0% | Moderate | |